Yanqiao Zhang

机构：Harbin Medical University, Bioscience Research, Third Affiliated Hospital of Harbin Medical University

发表论文 26 篇 · 总被引 250 次 · h-index 7

代表论文

• Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial (2020 · Clinical Cancer Research · 被引 116)
• First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. (2023 · Journal of Clinical Oncology · 被引 32)
• Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial (2024 · European Journal of Cancer · 被引 21)
• Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study (2022 · The Oncologist · 被引 14)
• Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China (2023 · European Journal of Cancer · 被引 13)
• Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial. (2021 · Journal of Clinical Oncology · 被引 11)